AbbVie Inc. $ABBV is Los Angeles Capital Management LLC’s 9th Largest Position

Los Angeles Capital Management LLC raised its position in AbbVie Inc. (NYSE:ABBV) by 0.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,331,629 shares of the company’s stock after acquiring an additional 7,343 shares during the quarter. AbbVie makes up about 1.8% of Los Angeles Capital Management LLC’s holdings, making the stock its 9th biggest holding. Los Angeles Capital Management LLC’s holdings in AbbVie were worth $532,078,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in the company. DB&C Advisors LLC purchased a new position in AbbVie in the fourth quarter worth approximately $4,737,000. Nemes Rush Group LLC lifted its stake in AbbVie by 1.0% in the fourth quarter. Nemes Rush Group LLC now owns 15,858 shares of the company’s stock worth $3,623,000 after acquiring an additional 157 shares during the last quarter. Mitchell Sinkler & Starr PA lifted its stake in AbbVie by 1.7% in the fourth quarter. Mitchell Sinkler & Starr PA now owns 13,727 shares of the company’s stock worth $3,136,000 after acquiring an additional 230 shares during the last quarter. 111 Capital lifted its stake in AbbVie by 68.7% in the fourth quarter. 111 Capital now owns 7,442 shares of the company’s stock worth $1,700,000 after acquiring an additional 3,031 shares during the last quarter. Finally, Peachtree Investment Partners LLC lifted its position in shares of AbbVie by 9.0% during the 4th quarter. Peachtree Investment Partners LLC now owns 2,126 shares of the company’s stock worth $486,000 after buying an additional 175 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Guggenheim reaffirmed a “buy” rating and issued a $249.00 target price on shares of AbbVie in a research report on Friday, May 1st. Barclays assumed coverage on shares of AbbVie in a research report on Thursday, February 19th. They issued an “overweight” rating and a $275.00 target price on the stock. Evercore set a $235.00 target price on shares of AbbVie in a research report on Friday, May 15th. BMO Capital Markets reaffirmed an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Finally, Morgan Stanley increased their target price on shares of AbbVie from $270.00 to $278.00 and gave the company an “overweight” rating in a research report on Thursday, April 30th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $253.43.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s ovarian cancer drug Elahere received a green light from the UK’s NHS / drug-cost watchdog, improving access and potential sales in a major international market. British drug-cost watchdog recommends use of AbbVie’s ovarian cancer therapy
• Positive Sentiment: AbbVie also won European Commission approval for Aquipta to treat migraine, which could expand the drug’s commercial opportunity in Europe. AbbVie receives EC approval for Aquipta to treat migraine
• Positive Sentiment: AbbVie’s FDA approval of Decnupaz for BPDCN was highlighted as validation of its ADC oncology strategy, reinforcing confidence in the company’s long-term cancer pipeline. Does Decnupaz Approval Validate ABBV’s ADC Strategy in Oncology?
• Positive Sentiment: AbbVie completed a real-world study of upadacitinib in China and finished a bioavailability study for ABBV-932, both of which support ongoing pipeline development. AbbVie Completes Real World Upadacitinib Study in China AbbVie Advances ABBV-932 With Completed Bioavailability Study
• Neutral Sentiment: AbbVie was also featured in value-stock and “cheap stocks” roundups, which may reflect its appeal to investors but are not direct company-specific catalysts. 5 Best Cheap Stocks to Buy for Beginners June 2026’s Top Stocks Estimated Below Intrinsic Value
• Negative Sentiment: AbbVie ended an early lung cancer trial for ABBV-647, which removes one potential upside driver from the oncology pipeline, though the broader impact appears limited. AbbVie Ends Early Lung Cancer Trial for ABBV-647

AbbVie Stock Performance

Shares of AbbVie stock opened at $227.68 on Friday. The company has a market cap of $402.27 billion, a P/E ratio of 112.16, a PEG ratio of 0.69 and a beta of 0.32. AbbVie Inc. has a one year low of $181.73 and a one year high of $244.81. The firm has a fifty day moving average of $209.85 and a two-hundred day moving average of $219.36.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, topping analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The business had revenue of $15 billion for the quarter, compared to analysts’ expectations of $14.72 billion. During the same period in the prior year, the company posted $2.46 EPS. The business’s revenue for the quarter was up 12.4% on a year-over-year basis. As a group, equities analysts predict that AbbVie Inc. will post 14.3 earnings per share for the current year.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.